Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

UnitedHealth Group Inc. appointed Wayne DeVeydt to become chief financial officer, replacing longtime finance chief John Rex.

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Backed by Bain Capital LP, the company has invited investment banks to pitch for roles in arranging the share sale, the ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...